Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission
Journal of Gastrointestinal and Liver Diseases · 22.12.2023 · 32 (4) · 452-459
DOI: 10.15403/jgld-5084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, online erschienen am 22.12.2023. Verfasst von Laura Parisio und 16 weiteren Autor:innen. Beteiligte Einrichtung: IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. . …. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims: Subcutaneous vedolizumab formulation has been shown to be as effective and safe as the intravenous one in randomized control trials. Real-life data are limited especially for patients receiving long-term intravenous therapy. This study aimed to evaluate the safety and effectiveness of switching from intravenous to subcutaneous vedolizumab in a large cohort of patients with stable clinical remission.
Methods
In this prospective cohort study, we enrolled consecutive patients attending our center between September 2021 and April 2022. The baseline demographic characteristics, 12- and 24-weeks follow-up clinical activity, C-reactive protein levels, and adverse events were recorded. The primary endpoint was to assess combined steroid-free clinical remission plus biochemical remission 24-week after the switch.
Results
93 patients (43 Crohn’s disease, 50 ulcerative colitis), switched to subcutaneous vedolizumab after a median duration of intravenous treatment of 36 months [IQR 16-52]. At baseline, 80 patients (86%) had a combined remission. At 24-week, 89.2% (n=74) maintained combined steroid-free clinical remission plus biochemical remission. 25 adverse events were reported, mostly SARS-CoV-2 infections and injection site reactions, with a further four recurrence episodes. Twelve patients (12.9%) discontinued subcutaneous administration and restarted intravenous vedolizumab.
Conclusions
Switching from intravenous to subcutaneous vedolizumab can be considered effective and safe for maintaining remission in patients with inflammatory bowel disease. In addition, this might reduce healthcare costs. However, large-scale real-life studies with long-term follow-up are necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. . laura.parisio@guest.policlinicogemelli.it.
- IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. carloromano.settanni@policlinicogemelli.it.
- IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sa…
- IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. laterza.lucrezia@gmail.com.
- IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome; Department of Medicine and Ageing Sciences, Center for Advanced Studies and Tec…
- IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. daniele.napolitano@policlinicogemelli.it.
Zitieren
APA
Parisio, L., Settanni, C. R., Varca, S., Laterza, L., Lopetuso, L. R., Napolitano, D., Schiavoni, E., Turchini, L., Fanali, C., Alfieri, N., Pizzoferrato, M., Papa, A., Pafundi, P. C., Armuzzi, A., Gasbarrini, A., Pugliese, D., & Scaldaferri, F. (2023). Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission. Journal of Gastrointestinal and Liver Diseases, 32(4), 452-459. https://doi.org/10.15403/jgld-5084
Vancouver
Parisio L, Settanni CR, Varca S, Laterza L, Lopetuso LR, Napolitano D, et al. Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission. Journal of Gastrointestinal and Liver Diseases. 2023;32(4):452-459. doi:10.15403/jgld-5084
BibTeX
@article{Parisio2023,
author = {Parisio, Laura and Settanni, Carlo Romano and Varca, Simone and Laterza, Lucrezia and Lopetuso, Loris Riccardo and Napolitano, Daniele and Schiavoni, Elisa and Turchini, Laura and Fanali, Caterina and Alfieri, Norma and Pizzoferrato, Marco and Papa, Alfredo and Pafundi, Pia Clara and Armuzzi, Alessandro and Gasbarrini, Antonio and Pugliese, Daniela and Scaldaferri, Franco},
title = {Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission},
journal = {Journal of Gastrointestinal and Liver Diseases},
year = {2023},
volume = {32},
number = {4},
pages = {452--459},
doi = {10.15403/jgld-5084}
}
EUVIMED